BioCentury | Mar 28, 2011
Financial News

China Medicine financial update

...due to its inability to meet the exchange's $4 minimum bid requirement for initial listing. China Medicine Corp....
BioCentury | Dec 6, 2010
Company News

China Medicine management update

China Medicine Corp. (OTCBB:CHME), Guangzhou, China Business: Pharmaceuticals Transitioned: VP of Finance and Accounting Henry Chi Fung Ho to CFO; he replaces Fred Cheung, who resigned WIR Staff...
BioCentury | Jan 11, 2010
Finance

JP Morgan's China play

...of JP Morgan Chase, One Equity Partners, made a $69.6 million bet last week on China Medicine Corp....
...received $12 million at closing, with the remaining $57.6 million to be placed in escrow. China Medicine...
...will use the proceeds to fund additional capital expenditures and acquisition projects. Under the agreement, China Medicine...
BioCentury | Jan 11, 2010
Financial News

China Medicine completes private placement of convertible preferred stock

China Medicine Corp. (OTCBB:CHME), Guangzhou, China Business: Pharmaceuticals Date completed: 1/7/10 Type: Private placement of convertible preferred stock Raised: $57.6 million Shares: 1.9 million Price: $30 Investor: One Equity Partners Note: Each preferred share is...
BioCentury | Jan 11, 2010
Financial News

China Medicine completes private placement

China Medicine Corp. (OTCBB:CHME), Guangzhou, China Business: Pharmaceuticals Date completed: 1/7/10 Type: Private placement Raised: $12 million Shares: 4 million Price: $3 Shares after offering: 19.3 million Investor: One Equity Partners WIR Staff...
BioCentury | Jan 8, 2010
Financial News

China Medicine raises $69.6 million

...million from the sale of preferred shares to be held in escrow and requested by China Medicine...
...10 common shares. One Equity Partners is the global private equity investment arm of JPMorgan. China Medicine...
...nutraceuticals and drugs in China, including iopamidol, an iodine-based contrast agent used in CNS imaging. China Medicine...
BioCentury | Mar 24, 2008
Product Development

TB partners

TB partners TB partners Vertex (NASDAQ:VRTX) has recruited a network of research organizations as collaborators in its TB drug development program, including labs working with TB in vitro, in animal models, and with human clinical...
Items per page:
1 - 7 of 7
BioCentury | Mar 28, 2011
Financial News

China Medicine financial update

...due to its inability to meet the exchange's $4 minimum bid requirement for initial listing. China Medicine Corp....
BioCentury | Dec 6, 2010
Company News

China Medicine management update

China Medicine Corp. (OTCBB:CHME), Guangzhou, China Business: Pharmaceuticals Transitioned: VP of Finance and Accounting Henry Chi Fung Ho to CFO; he replaces Fred Cheung, who resigned WIR Staff...
BioCentury | Jan 11, 2010
Finance

JP Morgan's China play

...of JP Morgan Chase, One Equity Partners, made a $69.6 million bet last week on China Medicine Corp....
...received $12 million at closing, with the remaining $57.6 million to be placed in escrow. China Medicine...
...will use the proceeds to fund additional capital expenditures and acquisition projects. Under the agreement, China Medicine...
BioCentury | Jan 11, 2010
Financial News

China Medicine completes private placement of convertible preferred stock

China Medicine Corp. (OTCBB:CHME), Guangzhou, China Business: Pharmaceuticals Date completed: 1/7/10 Type: Private placement of convertible preferred stock Raised: $57.6 million Shares: 1.9 million Price: $30 Investor: One Equity Partners Note: Each preferred share is...
BioCentury | Jan 11, 2010
Financial News

China Medicine completes private placement

China Medicine Corp. (OTCBB:CHME), Guangzhou, China Business: Pharmaceuticals Date completed: 1/7/10 Type: Private placement Raised: $12 million Shares: 4 million Price: $3 Shares after offering: 19.3 million Investor: One Equity Partners WIR Staff...
BioCentury | Jan 8, 2010
Financial News

China Medicine raises $69.6 million

...million from the sale of preferred shares to be held in escrow and requested by China Medicine...
...10 common shares. One Equity Partners is the global private equity investment arm of JPMorgan. China Medicine...
...nutraceuticals and drugs in China, including iopamidol, an iodine-based contrast agent used in CNS imaging. China Medicine...
BioCentury | Mar 24, 2008
Product Development

TB partners

TB partners TB partners Vertex (NASDAQ:VRTX) has recruited a network of research organizations as collaborators in its TB drug development program, including labs working with TB in vitro, in animal models, and with human clinical...
Items per page:
1 - 7 of 7